Clinical Trial: Treatment With Octreotide in Patients With Lymphangioleiomyomatosis

Study Status: Completed
Recruit Status: Completed
Study Type: Interventional




Official Title: Treatment With Octreotide in Patients With Lymphangioleiomyomatosis

Brief Summary: Lymphangioleiomyomatosis (LAM), a disease primarily of women of child-bearing age, is characterized by cystic lung disease and abdominal tumors (e.g., angiomyolipomas). Within the LAM patient population is a subset of patients who develop chylous effusions and lymphangioleiomyomas. Treatment of many of these symptoms has been ineffective. Previous studies with somatostatin and octreotide in other clinical settings have shown reduction in chylous effusions. This study assesses the effectiveness of octreotide in symptomatic patients with LAM, lymphangioleiomyomas and/or chylous effusions/ascites, peripheral lymphedema and chyluria.